VNRX logo

VNRX
VolitionRX Ltd

1,709
Mkt Cap
$22.49M
Volume
517,936.00
52W High
$18.80
52W Low
$1.91
PE Ratio
-0.74
VNRX Fundamentals
Price
$3.13
Prev Close
$2.70
Open
$2.89
50D MA
$3.12
Beta
0.45
Avg. Volume
201,790.10
EPS (Annual)
-$4.37
P/B
-0.78
Rev/Employee
$23,031.79
$36.31
Loading...
Loading...
News
all
press releases
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update PR Newswire HENDERSON...
News Placeholder
More News
News Placeholder
VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update PR Newswire...
News Placeholder
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
VolitionRx Announces Acceptance of Compliance Plan by NYSE American VolitionRx Announces Acceptance of Compliance Plan by NYSE American PR Newswire HENDERSON, Nev., April 23, 2026 HENDERSON, Nev...
News Placeholder
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update PR Newswire...
News Placeholder
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in...
News Placeholder
Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients
Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma...
News Placeholder
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update PR...
News Placeholder
VolitionRx Reports Over 95% Early Cancer Detection in Breakthrough Liquid Biopsy Study
VolitionRx Limited (NYSE:VNRX) unveiled promising new data that could reshape the landscape of early cancer detection, reporting over 95% sensitivity in identifying stage I and II cancers using its proprietary Capture-Seq liquid biopsy technology.
News Placeholder
VNRX Stock Soars 34% Pre-Market — What's Driving The Rally?
The company said it has developed a new liquid biopsy method, and in a blinded validation cohort, it achieved over 95% sensitivity for stage I & II cancers with 95% specificity.
News Placeholder
Volition Announces Detection of Over 95% of Early-Stage Cancers
Volition Announces Detection of Over 95% of Early-Stage Cancers Volition Announces Detection of Over 95% of Early-Stage Cancers PR Newswire HENDERSON, Nev., March 25, 2026 Blinded validation cohort...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available